DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Respiratory Syncytial Virus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Respiratory Syncytial Virus NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus (RSV) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Respiratory Syncytial Virus Pipeline Report
- DelveInsight’s analysis depicts a robust Respiratory Syncytial Virus Infection Pipeline with 50+ active players in the domain working on 50+ pipeline therapies.
- The leading Respiratory Syncytial Virus infection Companies includes Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others are under different phases of clinical trials for Respiratory Syncytial Virus.
- Promising Respiratory Syncytial Virus Infection Pipeline therapies such as RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, Research program: sirtuin targeted therapeutics for respiratory viral infections and others are under different phases of clinical trials for Respiratory Syncytial Virus (RSV).
- The Respiratory Syncytial Virus Infection companies and academics are working to assess challenges and seek opportunities that could influence Respiratory Syncytial Virus (RSV) R&D. The Respiratory Syncytial Virus Infection pipeline therapies under development are focused on novel approaches to treat/improve Respiratory Syncytial Virus (RSV).
To explore more information on the latest breakthroughs in the Respiratory Syncytial Virus Pipeline treatment landscape of the report, click here @ Respiratory Syncytial Virus Pipeline Outlook
Respiratory Syncytial Virus Overview
Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.
Recent Developments Activities in the Respiratory Syncytial Virus Treatment Landscape
- Enanta has selected EDP-938, a potent non-fusion inhibitor of both RSV-A and RSV-B activity, as its first development candidate for RSV.
- IVX-121 and IVX-A12 are the two vaccine candidates being developed by Icosavax, Inc. IVX-121 target Respiratory Syncytial Virus, a major cause of viral pneumonia for which no vaccine has been FDA approved.
- ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. The Bill & Melinda Gates Foundation (BMGF) has supported the Prepare trial for ResVax through a grant of up to $89.1 million; BMGF continues to financially support our efforts to conduct certain follow-up analyses of the Phase III data.
- In October 2020, Moderna, Inc., regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, known as MSD outside the United States and Canada, including rights to develop RSV vaccines for adult populations. mRNA-1172, which uses a Merck lipid nanoparticle for delivery, entered Phase 1 development in 2019. Under the terms of the agreement, Merck will complete the Phase 1 study and transition the program to Moderna.
- The development of V-306 Virometix offers a differentiated approach to RSV vaccine development. In Phase I clinical trial, V-306 demonstrated strong, durable, specific, and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease.
- Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live-attenuated vaccine candidate, to protect infants and at-risk older adults from RSV. MV-012-968 is currently in a Phase IIa, randomized, double-blind, placebo-controlled challenge study designed to evaluate the safety and prophylactic efficacy of the Meissa vaccine against symptomatic RSV infection.
Request a sample and discover the recent advances in Respiratory Syncytial Virus Pipeline Ongoing Clinical Trial Analysis and Medications, click here @ Respiratory Syncytial Virus Pipeline Treatment Landscape
Respiratory Syncytial Virus Emerging Drugs
GSK3844766A: GlaxoSmithKline
This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of development stage for the treatment of Respiratory Syncytial Virus (RSV).
Nirsevimab (MEDI-8897): MedImmune
MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of development stage.
Sisunatovir: ReViral
Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported. In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations.
Respiratory Syncytial Virus Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Respiratory Syncytial Virus (RSV). The companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.
For further information, refer to the detailed Respiratory Syncytial Virus Unmet Needs, Respiratory Syncytial Virus Market Drivers, and Market Barriers, click here for Respiratory Syncytial Virus Ongoing Clinical Trial Analysis
Scope of the Respiratory Syncytial Virus Pipeline Report
- Coverage- Global
- Respiratory Syncytial Virus infection Companies- Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others.
- Respiratory Syncytial Virus Infection Pipeline therapies- RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, and others.
- Respiratory Syncytial Virus Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Respiratory Syncytial Virus Market Drivers and Respiratory Syncytial Virus Market Barriers, click here @ Respiratory Syncytial Virus Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Respiratory Syncytial Virus (RSV): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Respiratory Syncytial Virus (RSV) Collaboration Deals
- Late Stage Products (Phase III)
- GSK3844766A: GlaxoSmithKline
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- EDP 938: Enanta Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- mRNA-1345: Moderna Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- AR-201: Aridis Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Respiratory Syncytial Virus (RSV) Key Companies
- Respiratory Syncytial Virus (RSV) Key Products
- Respiratory Syncytial Virus (RSV)- Unmet Needs
- Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
- Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
- Respiratory Syncytial Virus (RSV) Analyst Views
- Respiratory Syncytial Virus (RSV) Key Companies
- Appendix
Got Queries? Find out the related information on Respiratory Syncytial Virus Mergers and acquisitions, Respiratory Syncytial Virus Licensing Activities @ Respiratory Syncytial Virus Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services